WCF-598 RXRγ Degrader Data for Castration-Resistant Prostate Cancer

Encompassing experimental data related to the development of WCF-598, a potent and selective RXRγ degrader for treating castration-resistant prostate cancer (CRPC). The data supports findings from in vitro and in vivo studies, including tumor regression in 22Rv1 xenograft mouse models and secondary degradation of the AR-V7 splice variant. The dataset is 2.9 KB in size, but the specific row and column counts are unknown.

Use Cases

• Analyze the preferential degradation of RXRγ over RXRα and RXRβ isoforms to assess compound selectivity.
• Model the relationship between RXRγ degradation via the ubiquitin-proteasome system and observed antiproliferative activity in CRPC models.
• Investigate the secondary activity of WCF-598 on androgen receptor splice variant 7 (AR-V7) degradation and its implications for therapy resistance.
• Use data from 22Rv1 xenograft-bearing mice to correlate WCF-598 treatment with tumor regression metrics.

Strengths

• Data is derived from a published study establishing a specific chemical probe for a previously unrecognized target, RXRγ.
• The dataset includes in vivo results showing significant tumor regression in a mouse model without observable toxicity.
• Findings are supported by a secondary, clinically relevant mechanism involving degradation of the AR-V7 splice variant.

Limitations

• The dataset is very small at 2.9 KB, indicating limited scope and likely a summary of key results rather than raw experimental data.
• Specific data structure, including rows and columns, is unknown, limiting immediate analytical utility.
• Data is focused on a single compound (WCF-598) and specific cell line/xenograft models, which may limit generalizability.

Provenance

Source

figshare, authored by Chaofan Wang.

Collection Method

Experimental data generated from laboratory research utilizing the PROTAC approach and in vivo mouse models.

Freshness

2026-03-20